Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Trial watch

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.
Figure 2: Recruitment rates for trials involving anti-PD1/PDL1 therapies.


The authors thank D. Patel from IQVIA for supporting this report.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jun Tang.

Ethics declarations

Competing interests

JT, JXY, and VHL are employees of Cancer Research Institute and claim no conflicts of interests.

STN, JPH, YL and DP are employees of IQVIA and claim no conflicts of interests.

Supplementary information

Supplementary information

Supplementary information S1 (figure) (PDF 577 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Yu, J., Hubbard-Lucey, V. et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17, 854–855 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research